Ascendis Pharma A (ASND) Net Cash Flow (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Net Cash Flow data on file, last reported at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 72.83% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$113.3 million (down 153.56% YoY), and the FY2025 full-year result was -$92.0 million, down 158.78% from the prior year.
• Net Cash Flow grew to -$60.1 million in Q1 2026, from -$95.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $407.7 million in Q3 2024 to a low of -$142.9 million in Q4 2022.
• A 5-year average of -$2.7 million and a median of -$60.1 million in 2026 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 816.62% in 2024, while the deepest fall reached 222.3% in 2024.
• Tracing ASND's Net Cash Flow over 5 years: stood at -$142.9 million in 2022, then jumped by 68.48% to -$45.1 million in 2023, then tumbled by 107.43% to -$93.5 million in 2024, then slipped by 2.46% to -$95.8 million in 2025, then surged by 37.27% to -$60.1 million in 2026.
• Business Quant data shows ASND's Net Cash Flow at -$60.1 million in Q1 2026, -$95.8 million in Q4 2025, and $47.9 million in Q3 2025.